
Clinical trial investigates oral MRGPRX2 antagonist in urticaria
The first patient has been treated in a Phase II trial of EVO756 in adults with chronic inducible urticaria (CIndU). EVO756 is a highly selective small molecule antagonist of mas-related G-protein coupled receptor X2 (MRGPRX2) and could offer the potential for once-daily oral administration without the… Read More
